Illustration credit to Nora Howie
Many of us have experienced butterflies in our stomach, trusting our gut instinct, or feeling sick with anxiety. The connection between our emotional state and gut is so familiar that it it embedded in everyday language. What we are slowly realising is that this relationship might just be a two-way street: changes in our gut could influence what happens in the brain.
Growing experimental evidence suggests that signals originating in the gastrointestinal tract, and in particular its microbial inhabitants, may influence stress responses, behaviour, and brain function. Discoveries from DNA sequencing, animal models, and transplantation experiments have introduced an exciting prospect: if changes in the gut can contribute to psychiatric symptoms, could manipulating the microbiome eventually help to treat them?
Rethinking the mind
Traditionally, psychiatric disorders were thought of as principally disorders of the mind. However, the relationship between the gut and the brain has been recognised for a long time, considering that the two develop from the same embryonic tissue. It has been believed that anxiety and depression have contributed to symptoms of irritable bowel syndrome and functional bowel issues. The enteric nervous system (ENS) made of over 100 million nerve cells in two thin layers is often described as a ‘second brain’ and allows the gut to control digestion and communication signals independent of the central nervous system.
Increasingly, attention has turned beyond the ENS to the gut microbiota which refers to the complex community of trillions of microorganisms living in the digestive tract. They form a unique ecosystem facilitating bodily functions such as digestion and nutrient production. They can influence the production and regulation of neurotransmitters, such as serotonin and GABA, and generate metabolites capable of interacting with neural, immune, and endocrine pathways. Its composition is remarkably dynamic, responding to age, disease, medication, diet, and more. Together, these interactions provide several potential routes through which changes within in the gut could communicate with the brain, and potentially in turn through which the brain could alter the gastrointestinal environment.
Germ free mice develop in the absence of a normal microbial population. They provide some exciting evidence as they have been shown to have less than half the standard amount of serotonin in the gastrointestinal tract. Additionally, they exhibit an exaggerated hormonal response involving cortisol and adrenaline when exposed to stress. Introducing normal gut bacteria, however, has been shown to modify this response, suggesting that microbe exposure may contribute to development of systems regulating stress. Such experiments and models begin to shift the microbiome not only as a correlate of psychiatric states, but as a participant to underlying biology. Other mice models include faecal microbiota transplantation experiments (FMT). In these experiments, recipient mice adopted behavioural traits of their donor, including anxiety, depressive-like immobility, and social deficits, providing a new string of evidence for a causal relationship between the two. Experiments are powerful, showing us not only association between the gut and the brain, but introducing potential areas for manipulation.
From Gut to Head
Several mechanisms have been proposed to explain how changes within the gut could influence psychiatric function. One of the most direct routes is the neural communication through the vagus nerve, connecting the brainstem to the gastrointestinal tract. Chemical signals produced by the gut microbiota can stimulate sensory nerve endings within the intestinal wall, allowing information from the gut to be transmitted to the CNS. These can also influence neurochemical and metabolic signalling by neurotransmitters, as well as producing short-chain fatty acids through the digestion of dietary fibre. A further pathway may involve the immune system. Disruption of the intestinal barrier may allow bacterial components such as lipopolysaccharides to enter the circulation, triggering the release of inflammatory cytokines that can influence the brain and promote microglial activation. Moreover, this relationship could interact through the hypothalamic-pituitary-adrenal axis, explaining its role in the endocrine stress response. Dysregulation of this system can lead to prolonged cortisol elevations which can in turn affect brain regions involved in mood regulation. Together these pathways suggest that communication between the gut and the brain is unlikely to depend on a single mechanism, instead arising from an interconnected network through which changes in the gastrointestinal environment may influence brain function and behaviour.
From Mice to Man
Expanding areas of research look to involve humans to see how this relationship functions, and more importantly, shift our attention to look at how this might be manipulated for treatment. In 2023, a randomised controlled clinical trial investigated active FMT administered via enema, against placebo in psychiatric patients and was found to be a safe mechanism of improving quality of life outcomes. It led to the investigation of whether oral, capsule-based or enema-administered FMT alongside standard antidepressants could pave a new pathway for treatment. A clinical study in 2026 showed those receiving such supporting treatment experienced a significantly greater reduction in depression severity. Although these findings are encouraging, larger and longer-term clinical trials will be required to establish whether such interventions can produce consistent and clinically meaningful improvements in symptoms.
Looking at earlier stages of life, such as early microbial colonisation could identify whether this affects brain development, for example in sensory processing and behavioural traits often seen in neurodivergence. However, establishing causality in humans remains challenging given the considerable variation in microbiome compositions and the numerous factors influencing it.
Emerging research is studying the extracellular vesicles secreted by bacteria. Understanding their role and how they cross the blood brain barrier could help us to explore them as natural delivery vehicles for therapeutic signals or potential biomarkers for psychiatric conditions.
From Microbe to Medicine
A greater understanding of this axis could create new opportunities for treating psychiatric disorders by targeting the microbiome alongside conventional therapies. One emerging approach is the development of targeted ‘psychobiotics’: specific strains of live microorganisms selected for their potential to produce neuroactive compounds and promote beneficial metabolites that may influence psychological stress responses. Rather than administering the microorganisms themselves, researchers are also investigating microbiome-targeted drug discovery. This would involve identifying and isolating specific metabolites that directly influence signalling and potential develop these into therapeutic agents. There is also room for treatment to become highly personalised in a field known as precision nutritional psychiatry. By identifying an individual’s unique gut microbial composition, specific dietary interventions could be made to encourage shifts in the microbiome towards those with beneficial metabolic effects. These approaches focus on other pathways of the gut-brain relationship beyond those targeted by conventional psychiatric medication. However, these are perhaps best viewed as potential adjuncts rather than replacements for established treatments. As mechanisms have become better understood, manipulating this relationship may ultimately provide another tool through which treatment can be tailored to complex, individual biology that underlies psychiatric disorders.
Illustration credit to Nora Howie
Many of us have experienced butterflies in our stomach, trusting our gut instinct, or feeling sick with anxiety. The connection between our emotional state and gut is so familiar that it it embedded in everyday language. What we are slowly realising is that this relationship might just be a two-way street: changes in our gut could influence what happens in the brain.
Growing experimental evidence suggests that signals originating in the gastrointestinal tract, and in particular its microbial inhabitants, may influence stress responses, behaviour, and brain function. Discoveries from DNA sequencing, animal models, and transplantation experiments have introduced an exciting prospect: if changes in the gut can contribute to psychiatric symptoms, could manipulating the microbiome eventually help to treat them?
Rethinking the mind
Traditionally, psychiatric disorders were thought of as principally disorders of the mind. However, the relationship between the gut and the brain has been recognised for a long time, considering that the two develop from the same embryonic tissue. It has been believed that anxiety and depression have contributed to symptoms of irritable bowel syndrome and functional bowel issues. The enteric nervous system (ENS) made of over 100 million nerve cells in two thin layers is often described as a ‘second brain’ and allows the gut to control digestion and communication signals independent of the central nervous system.
Increasingly, attention has turned beyond the ENS to the gut microbiota which refers to the complex community of trillions of microorganisms living in the digestive tract. They form a unique ecosystem facilitating bodily functions such as digestion and nutrient production. They can influence the production and regulation of neurotransmitters, such as serotonin and GABA, and generate metabolites capable of interacting with neural, immune, and endocrine pathways. Its composition is remarkably dynamic, responding to age, disease, medication, diet, and more. Together, these interactions provide several potential routes through which changes within in the gut could communicate with the brain, and potentially in turn through which the brain could alter the gastrointestinal environment.
Germ free mice develop in the absence of a normal microbial population. They provide some exciting evidence as they have been shown to have less than half the standard amount of serotonin in the gastrointestinal tract. Additionally, they exhibit an exaggerated hormonal response involving cortisol and adrenaline when exposed to stress. Introducing normal gut bacteria, however, has been shown to modify this response, suggesting that microbe exposure may contribute to development of systems regulating stress. Such experiments and models begin to shift the microbiome not only as a correlate of psychiatric states, but as a participant to underlying biology. Other mice models include faecal microbiota transplantation experiments (FMT). In these experiments, recipient mice adopted behavioural traits of their donor, including anxiety, depressive-like immobility, and social deficits, providing a new string of evidence for a causal relationship between the two. Experiments are powerful, showing us not only association between the gut and the brain, but introducing potential areas for manipulation.
From Gut to Head
Several mechanisms have been proposed to explain how changes within the gut could influence psychiatric function. One of the most direct routes is the neural communication through the vagus nerve, connecting the brainstem to the gastrointestinal tract. Chemical signals produced by the gut microbiota can stimulate sensory nerve endings within the intestinal wall, allowing information from the gut to be transmitted to the CNS. These can also influence neurochemical and metabolic signalling by neurotransmitters, as well as producing short-chain fatty acids through the digestion of dietary fibre. A further pathway may involve the immune system. Disruption of the intestinal barrier may allow bacterial components such as lipopolysaccharides to enter the circulation, triggering the release of inflammatory cytokines that can influence the brain and promote microglial activation. Moreover, this relationship could interact through the hypothalamic-pituitary-adrenal axis, explaining its role in the endocrine stress response. Dysregulation of this system can lead to prolonged cortisol elevations which can in turn affect brain regions involved in mood regulation. Together these pathways suggest that communication between the gut and the brain is unlikely to depend on a single mechanism, instead arising from an interconnected network through which changes in the gastrointestinal environment may influence brain function and behaviour.
From Mice to Man
Expanding areas of research look to involve humans to see how this relationship functions, and more importantly, shift our attention to look at how this might be manipulated for treatment. In 2023, a randomised controlled clinical trial investigated active FMT administered via enema, against placebo in psychiatric patients and was found to be a safe mechanism of improving quality of life outcomes. It led to the investigation of whether oral, capsule-based or enema-administered FMT alongside standard antidepressants could pave a new pathway for treatment. A clinical study in 2026 showed those receiving such supporting treatment experienced a significantly greater reduction in depression severity. Although these findings are encouraging, larger and longer-term clinical trials will be required to establish whether such interventions can produce consistent and clinically meaningful improvements in symptoms.
Looking at earlier stages of life, such as early microbial colonisation could identify whether this affects brain development, for example in sensory processing and behavioural traits often seen in neurodivergence. However, establishing causality in humans remains challenging given the considerable variation in microbiome compositions and the numerous factors influencing it.
Emerging research is studying the extracellular vesicles secreted by bacteria. Understanding their role and how they cross the blood brain barrier could help us to explore them as natural delivery vehicles for therapeutic signals or potential biomarkers for psychiatric conditions.
From Microbe to Medicine
A greater understanding of this axis could create new opportunities for treating psychiatric disorders by targeting the microbiome alongside conventional therapies. One emerging approach is the development of targeted ‘psychobiotics’: specific strains of live microorganisms selected for their potential to produce neuroactive compounds and promote beneficial metabolites that may influence psychological stress responses. Rather than administering the microorganisms themselves, researchers are also investigating microbiome-targeted drug discovery. This would involve identifying and isolating specific metabolites that directly influence signalling and potential develop these into therapeutic agents. There is also room for treatment to become highly personalised in a field known as precision nutritional psychiatry. By identifying an individual’s unique gut microbial composition, specific dietary interventions could be made to encourage shifts in the microbiome towards those with beneficial metabolic effects. These approaches focus on other pathways of the gut-brain relationship beyond those targeted by conventional psychiatric medication. However, these are perhaps best viewed as potential adjuncts rather than replacements for established treatments. As mechanisms have become better understood, manipulating this relationship may ultimately provide another tool through which treatment can be tailored to complex, individual biology that underlies psychiatric disorders.